Anthropic steps up AI drug discovery efforts, CEO eyes cancer breakthroughs
Anthropic is collaborating with multiple biotechnology firms to leverage AI in drug development, targeting conditions like cancer and muscular dystrophy.
Latest news, updates and analysis on Claude AI
Anthropic is collaborating with multiple biotechnology firms to leverage AI in drug development, targeting conditions like cancer and muscular dystrophy.
As AI developer Anthropic prepares for a potential stock market listing, the company faces scrutiny over its unique origins and its refusal to meet Pentagon requirements.
The maker of Claude chatbot is seeking to raise over $90 billion through a public offering and private investment as it prepares to go public next week.
Artificial intelligence giant Anthropic has reported a significant surge in its financial performance, with revenues climbing to $16.8 billion for the three-month period ending in September. This repr...